ID   NTAN1_HUMAN             Reviewed;         310 AA.
AC   Q96AB6; Q7Z4Z0;
DT   26-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   15-MAR-2017, entry version 108.
DE   RecName: Full=Protein N-terminal asparagine amidohydrolase;
DE            EC=3.5.1.-;
DE   AltName: Full=Protein NH2-terminal asparagine amidohydrolase;
DE            Short=PNAA;
DE   AltName: Full=Protein NH2-terminal asparagine deamidase;
DE            Short=PNAD;
DE            Short=Protein N-terminal Asn amidase;
DE            Short=Protein N-terminal asparagine amidase;
DE            Short=Protein NTN-amidase;
GN   Name=NTAN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jiang C.L., Yu L., Fan Y.X., Tu Q., Jiang J.X., Zhao S.Y.;
RT   "Cloning and expression of a novel human cDNA homology to murine N-
RT   terminal asparagine amidohydrolase (Ntan1) mRNA.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, REMOVAL OF INITIATOR METHIONINE, AND MUTAGENESIS OF PRO-2
RP   AND CYS-75.
RX   PubMed=21375249; DOI=10.1021/bi101832w;
RA   Cantor J.R., Stone E.M., Georgiou G.;
RT   "Expression and biochemical characterization of the human enzyme N-
RT   terminal asparagine amidohydrolase.";
RL   Biochemistry 50:3025-3033(2011).
CC   -!- FUNCTION: Side-chain deamidation of N-terminal asparagine residues
CC       to aspartate. Required for the ubiquitin-dependent turnover of
CC       intracellular proteins that initiate with Met-Asn. These proteins
CC       are acetylated on the retained initiator methionine and can
CC       subsequently be modified by the removal of N-acetyl methionine by
CC       acylaminoacid hydrolase (AAH). Conversion of the resulting N-
CC       terminal asparagine to aspartate by PNAD renders the protein
CC       susceptible to arginylation, polyubiquitination and degradation as
CC       specified by the N-end rule. This enzyme does not act on
CC       substrates with internal or C-terminal asparagines and does not
CC       act on glutamine residues in any position, nor on acetylated N-
CC       terminal peptidyl Asn. {ECO:0000269|PubMed:21375249}.
CC   -!- ENZYME REGULATION: Inhibited by micromolar concentrations of
CC       copper and zinc ions. {ECO:0000269|PubMed:21375249}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.0-7.5. {ECO:0000269|PubMed:21375249};
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF092440; AAP97215.1; -; mRNA.
DR   EMBL; BC017336; AAH17336.1; -; mRNA.
DR   CCDS; CCDS10558.1; -.
DR   RefSeq; NP_001257695.1; NM_001270766.1.
DR   RefSeq; NP_001257696.1; NM_001270767.1.
DR   RefSeq; NP_775745.1; NM_173474.3.
DR   UniGene; Hs.592045; -.
DR   ProteinModelPortal; Q96AB6; -.
DR   SMR; Q96AB6; -.
DR   BioGrid; 125835; 2.
DR   IntAct; Q96AB6; 1.
DR   STRING; 9606.ENSP00000287706; -.
DR   iPTMnet; Q96AB6; -.
DR   PhosphoSitePlus; Q96AB6; -.
DR   DMDM; 37082118; -.
DR   EPD; Q96AB6; -.
DR   MaxQB; Q96AB6; -.
DR   PaxDb; Q96AB6; -.
DR   PeptideAtlas; Q96AB6; -.
DR   PRIDE; Q96AB6; -.
DR   DNASU; 123803; -.
DR   Ensembl; ENST00000287706; ENSP00000287706; ENSG00000157045.
DR   Ensembl; ENST00000620176; ENSP00000484380; ENSG00000275779.
DR   GeneID; 123803; -.
DR   KEGG; hsa:123803; -.
DR   UCSC; uc002ddd.5; human.
DR   CTD; 123803; -.
DR   DisGeNET; 123803; -.
DR   GeneCards; NTAN1; -.
DR   HGNC; HGNC:29909; NTAN1.
DR   HPA; HPA051418; -.
DR   MIM; 615367; gene.
DR   neXtProt; NX_Q96AB6; -.
DR   OpenTargets; ENSG00000157045; -.
DR   PharmGKB; PA134863573; -.
DR   eggNOG; ENOG410IE4U; Eukaryota.
DR   eggNOG; ENOG410XW2S; LUCA.
DR   GeneTree; ENSGT00390000016730; -.
DR   HOGENOM; HOG000047800; -.
DR   HOVERGEN; HBG052674; -.
DR   InParanoid; Q96AB6; -.
DR   KO; K14662; -.
DR   OMA; CLAHCDG; -.
DR   OrthoDB; EOG091G09RF; -.
DR   PhylomeDB; Q96AB6; -.
DR   TreeFam; TF325597; -.
DR   GenomeRNAi; 123803; -.
DR   PRO; PR:Q96AB6; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000157045; -.
DR   CleanEx; HS_NTAN1; -.
DR   ExpressionAtlas; Q96AB6; baseline and differential.
DR   Genevisible; Q96AB6; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0008418; F:protein-N-terminal asparagine amidohydrolase activity; IEA:Ensembl.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   InterPro; IPR026750; NTAN1.
DR   PANTHER; PTHR12498; PTHR12498; 1.
DR   Pfam; PF14736; N_Asn_amidohyd; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Cytoplasm; Hydrolase; Polymorphism;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:Q28955}.
FT   CHAIN         2    310       Protein N-terminal asparagine
FT                                amidohydrolase.
FT                                /FTId=PRO_0000057971.
FT   SITE         75     75       Essential for catalytic activity.
FT   VARIANT     283    283       H -> N (in dbSNP:rs1136001).
FT                                /FTId=VAR_051244.
FT   VARIANT     287    287       S -> P (in dbSNP:rs1135999).
FT                                /FTId=VAR_051245.
FT   MUTAGEN       2      2       P->G: 3-fold reduction in catalytic
FT                                activity. {ECO:0000269|PubMed:21375249}.
FT   MUTAGEN      75     75       C->A,S,T: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:21375249}.
FT   CONFLICT      6      6       E -> D (in Ref. 1; AAP97215).
FT                                {ECO:0000305}.
FT   CONFLICT     14     14       Q -> R (in Ref. 1; AAP97215).
FT                                {ECO:0000305}.
SQ   SEQUENCE   310 AA;  34677 MW;  C7FE8C550883DFC3 CRC64;
     MPLLVEGRRV RLPQSAGDLV RAHPPLEERA RLLRGQSVQQ VGPQGLLYVQ QRELAVTSPK
     DGSISILGSD DATTCHIVVL RHTGNGATCL THCDGTDTKA EVPLIMNSIK SFSDHAQCGR
     LEVHLVGGFS DDRQLSQKLT HQLLSEFDRQ EDDIHLVTLC VTELNDREEN ENHFPVIYGI
     AVNIKTAEIY RASFQDRGPE EQLRAARTLA GGPMISIYDA ETEQLRIGPY SWTPFPHVDF
     WLHQDDKQIL ENLSTSPLAE PPHFVEHIRS TLMFLKKHPS PAHTLFSGNK ALLYKKNEDG
     LWEKISSPGS
//
